Document is current
Any future updates will be listed below
-
Authors
Mitratza, Marianna https://orcid.org/0000-0002-1573-2015
Elsobky, Malak https://orcid.org/0009-0003-3175-7823
Liang, Caihua https://orcid.org/0009-0004-8375-631X
Bruyndonckx, Robin https://orcid.org/0000-0002-4217-2869
Polkowska-Kramek, Aleksandra https://orcid.org/0000-0003-0148-7183
Ewnetu, Worku Biyadgie https://orcid.org/0000-0002-3650-2016
Peerawaranun, Pimnara https://orcid.org/0000-0002-3746-6846
Tran, Thao Mai Phuong https://orcid.org/0000-0003-2336-8302
Nuttens, Charles
Grajales, Ana Gabriela
Nzula, Sazini
Gessner, Bradford D.
Begier, Elizabeth
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 1 April 2024
Accepted: 2 July 2024
First Online: 15 July 2024
Declarations
:
: Marianna Mitratza, Robin Bruyndonckx, Aleksandra Polkowska-Kramek, Worku Biyadgie Ewnetu, Pimnara Peerawaranun, and Thao Mai Phuong Tran are employees of P95 Epidemiology & Pharmacovigilance, which received funding from Pfizer to conduct the research described in this manuscript and for manuscript development. Malak Elsobky, Caihua Liang, Charles Nuttens, Ana Gabriela Grajales, Sazini Nzula, Bradford D. Gessner, and Elizabeth Begier are Pfizer employees and may own Pfizer stock.
: The study received ethics approval from the Advarra Institutional Review Board (Study number Pro00068118). The study was conducted in accordance with legal and regulatory requirements and research practices described in the Good Epidemiological Practice guidelines issued by the International Epidemiological Association.
